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Spinal muscular atrophy (SMA) is caused by low levels of survival of motor 
neuron (SMN) protein. A growing number of potential therapeutic strategies for 
SMA are entering pre-clinical and clinical testing, including gene therapy and 
antisense oligonucleotide-based approaches. For many such studies SMN protein 
levels are used as a readout of treatment efficacy, often necessitating 
comparisons between samples obtained at different times and/or using different 
protocols. Whether differences in tissue sampling strategies or storage 
parameters have an influence on SMN stability remains to be determined. We 
assessed murine SMN protein stability over time and under differing tissue 
storage conditions. SMN protein levels, measured using sensitive quantitative 
fluorescent western blotting, declined rapidly over a period of several days 
following sample collection, especially when protein was extracted immediately 
and stored at -20oC. We demonstrate that storage of samples at lower 
temperatures (-80oC), and as intact tissue, led to significantly better preservation 
of SMN immunoreactivity. However, considerable deterioration in SMN levels 
occurred even under optimal storage conditions. These findings need to be taken 
into consideration for both the design and interpretation of pre-clinical and 







Proximal spinal muscular atrophy (SMA) is a leading genetic cause of infant 
mortality in humans, occurring with an incidence of 1 in 6000 live births [1]. 
SMA is an autosomal recessive disease caused by homozygous deletion or 
mutation of the ubiquitously expressed survival of motor neuron 1 (SMN1) gene 
[2]. In humans, there are two SMN genes, SMN1 and SMN2. The SMN2 gene 
produces considerably less SMN protein than the SMN1 gene meaning that it 
cannot fully compensate when full-length SMN protein from the SMN1 gene is 
lost [3, 4]. In its most severe forms, disease onset occurs before six months of age 
with death from respiratory distress usually within 1-2 years. The major 
pathological characteristic of SMA is loss of lower alpha motor neurons from the 
ventral horn of the spinal cord, resulting in progressive muscle denervation and 
atrophy, particularly of the proximal muscles. 
There is currently no successful treatment or cure for SMA. However, several 
novel therapeutic approaches are showing promise in pre-clinical studies, such 
as gene therapy [5-9], anti-sense oligonucleotides [10-14], histone deacetylase 
(HDAC) inhibitors [15-19], and beta-catenin inhibitors [19]. Indeed, several of 
these approaches are entering clinical trials in patients. 
In the absence of an established panel of robust SMA biomarkers [20], SMN 
levels are often used as a major biological read-out to evaluate therapeutic 
efficacy [5, 14, 21]. However, proteins can be unstable when outside their native 
environment. If this scenario were applicable to SMN, it is possible that patient 
or animal tissue samples obtained at different times and/or processed and 
stored in different ways (e.g. as is likely to occur in a multi-centre clinical trial on 
patients) could show differing levels of SMN protein as a consequence of 
different handling protocols rather than due to differences in SMN levels per se. 
As far as we are aware, no prospective studies evaluating levels of SMN stability 
and preservation under different tissue preparation and storage conditions have 
been reported. Here, we attempted to address this potentially important issue 
by analyzing frozen tissue samples and protein extracts stored at two standard 
storage temperatures (-20 oC and -80 oC) covering a period of 6 months. SMN 
protein levels were evaluated across a range of time points using both 
commercial and academically-available antibodies. 
 
2. Materials and Methods 
Animal models. Young adult wild-type CD1 mice were obtained from in-house 
breeding stocks at the University of Edinburgh. All mice were housed within the 
animal care facilities in Edinburgh under standard SPF conditions. All animal 
procedures were performed in accordance with UK Home Office and institutional 
guidelines. 
 
Tissue processing and quantitative fluorescent western blotting. Fresh 
spinal cord tissue was dissected and immediately frozen on dry ice. Tissue and 
protein extracts were stored at -20 oC or -80 oC for 1, 7 days (d) or 4, 8, 12, 16, 
20, 24 weeks (wk). Samples from 3 independent animals were used for each 
timepoint and storage parameter examined. Protein extracts were prepared 
from frozen tissue on the day of harvest. Protein extracts were prepared from 
frozen tissue in RIPA buffer (ThermoScientific) with a protease inhibitor cocktail 
(Sigma). Tissue was defrosted in RIPA buffer on ice, homogenised using a 
motorised pestle, then immediately placed in a 4 oC centrifuge and spun at 14000 
rpm for 30 minutes. Protein extracts were removed and stored on ice until 
analyses (< 1 hr). Prior to analyses, protein extracts were quantified alongside a 
freshly collected tissue sample. Quantitative western blots were performed 
using 25g protein, primary antibodies against SMN (MANSMA12, mouse, 1:100; 
gift [22] and BD-SMN, mouse; 1:500; BD Transduction Labs) and COXIV (mouse; 
1:2500; Abcam). Odyssey secondary antibodies were added according to the 
manufacturers’ instructions (goat anti-mouse IRDye 680). Blots were imaged 
using an Odyssey Infrared Imaging System (Li-COR, Biosciences) at a resolution 
of 169 M. Each blot was scanned and measured in triplicate to minimise user 
variability. Each sample was normalised against a COXIV loading control and 
then normalised to levels obtained in freshly prepared samples (harvested on 
the day of the experiment). 
 
Statistical analysis. All data were collected using Microsoft Excel and analysed 
using GraphPad Prism software. For all statistical analyses, p < 0.05 was 
considered to be significant. All data are expressed as mean SEM. 
 
3. Results 
COXIV protein does not degrade over time. 
To establish that we could reliably extract, store and quantify protein levels 
across multiple samples we carried out preliminary analyses of COXIV protein, a 
mitochondrial marker routinely used as a normalising control. Samples were 
stored as intact tissue or protein extracts for selected time points (1 d, 4 wk, 8 
wk, 24 wk) at -20 and -80 oC, before quantifying COXIV levels. We demonstrate 
that COXIV levels were both qualitatively (Fig. 1A) and quantitatively (Fig. 1B) 
preserved from 1d up to at least 24 wk at -20 and -80 oC. From our initial data, 
we can conclude that western blotting methodology is suitable for such 
prospective analyses and that COXIV is an appropriate loading control to 
evaluate SMN protein levels over a similar 24 wk time period. 
 
Detection of SMN protein with commercial and academic primary antibodies. 
To establish whether different primary antibodies used to measure SMN protein 
levels varied in their ability to detect SMN protein, we initially compared SMN 
levels from tissue and protein extracts stored for selected time points (1, 7 d or 
4, 8, 12, 16, 20, 24 wk) at a standard storage condition (-20 oC) (Fig. 2). There 
was no significant difference in the levels of SMN protein detected at any time 
point using either the commercially-available or academically-available SMN 
antibodies tested in this study (BD Transduction Laboratories and MANSMA12 
[22]) (Fig. 2B). Both antibodies detected similar levels of SMN, regardless of how 
the tissue had been processed, with both antibodies revealing a robust decline in 
measured SMN protein levels of a period of 24 wk in storage (Fig. 2A and B). 
 
Detectable SMN levels reduce after 7 days storage. 
To determine whether SMN levels degraded similarly under different storage 
conditions, we first compared the effects of storage at -20 oC comapred to -80 oC. 
After 24 wk, levels of SMN were visibly reduced at both storage temperatures, 
with a greater degradation observed when stored at -20 oC (Fig. 3A). The level of 
SMN protein detectable by quantitative western blotting was reduced after only 
7 d of storage at both -20 oC and -80 oC (Fig. 3B). A particularly high decrease in 
SMN levels was observed in samples stored at -20 oC, particularly between 1 d 
and 7 d (from 77.5 % of levels detected in fresh samples at 1 d down to 35.8 % at 
7 d). A smaller decrease was detected during the same time period with samples 
stored at -80 oC (88.7 % down to 76.3 % at 1 d and 7 d respectively). Detectable 
levels of SMN protein continued to reduce over time under both storage 
conditions, but the greatest overall drop was observed in samples stored at -20 
oC (Fig. 3B). Indeed, there was a significant difference in levels of detectable SMN 
from samples stored at -20 oC and -80 oC at the majority of time points from 7 d 
onwards, with SMN levels more stably preserved at -80 oC (Fig. 3). At all time 
points examined, samples stored at -80 oC retained more than 50 % of SMN 
levels observed in fresh samples. 
 
Extended preservation of SMN when samples are stored as frozen tissue. 
Samples stored at -20 oC originating from both frozen tissue and protein extracts 
retained less than 50% of the SMN levels detectable in a fresh sample by 7 d 
(protein extract) and 4 wk (frozen tissue) (Fig. 4A). Although variable between 
time points, storage of samples as frozen tissue at -20 oC retained higher levels of 
SMN than samples stored as protein extracts. This was significantly different at 
the majority of time points tested (Fig. 4A). When stored at -80 oC, SMN levels 
were preserved above 50 % until at least 12 wk (protein extract) and 24 wk 
(frozen protein) (Fig. 4B). SMN levels from frozen tissue were higher than in 
protein extracts stored for the same time (Fig. 4B). At the longest time point 
tested (24 wk) SMN levels were highest in frozen tissue stored at -80 oC, (88.5 % 
of fresh) compared to 27.7 % in protein extracts. 
 
4. Discussion 
Here, we have demonstrated that detectable levels of SMN protein in in vivo 
samples decline over a fairly short period of time, regardless of the tissue 
handling protocols employed or the temperature used for storage. However, we 
also established that SMN protein remained more stable in samples stored as 
whole tissue rather than as extracted protein, with clear benefits of storing at -80 
oC over -20 oC. 
There is no cure for SMA, however, a number of novel therapeutics that are 
currently undergoing pre-clinical testing or clinical trials aim to affect disease 
progression by increasing levels of SMN protein. SMN levels are routinely 
measured to determine the efficacy of such therapeutics; however, given the 
instability of SMN demonstrated here, it is crucial to have an informed 
understanding of the degradation process to instigate best practise in terms of 
tissue collection and storage prior to analyses, thus improving study design and 
accurate interpretation of SMN level data. We propose that to maintain the 
highest possible levels of SMN protein from biological tissue samples it is best to 
flash freeze samples at a temperature of at least -80 oC and perform experiments 
to determine protein levels as quickly as possible after tissue sampling. 
To minimise inter-sample variability and improve comparative analyses in preclinical 
or clinical trials, we suggest that if all required samples cannot be 
collected at the same time (as is often in the case in large pre-clinical animal 
studies and multi-centre clinical trials), then an equal number of control and 
SMA samples should collected in parallel and stored identically. Our findings 
suggest that comparative analyses should preferentially be carried out on 
samples collected at the same time to minimise differential SMN levels occurring 
due to differential SMN degradation associated with tissue processing and/or 
storage. 
Overall, our findings highlight precautions that should be taken when using SMN 
protein levels as a therapeutic readout and/or biomarker, and highlight the 
importance of understanding sample handling and storage parameters for 
designing appropriate pre-clinical and clinical studies for SMA. 
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Figure legends 
Fig. 1. COXIV levels are stable over 24 wk. (A) Representative blots 
demonstrating stable COXIV protein levels independent of storage temperature 
at 1 d, 28 d (4 wk), 84 d (12 wk) and 168 d (24 wk) (all blots prepared from 
samples stored as frozen tissue and using BD antibody). (B) Graphic 
representation of stable COXIV levels at 1, 28, 84 and 168 d, expressed per blot 
relative to levels of COXIV in a freshly harvested protein sample. 
Fig. 2. Identical performance of academic and commercially available SMN 
antibodies. (A) Representative blots of SMN levels detected at 1 d, 56 d (8 wk) 
and 168 d (24 wk) using two SMN antibodies (BD, BD Transduction 
Laboratories and MANSMA12) (all blots prepared from samples stored as frozen 
tissue). (B) Graph demonstrating that identical levels of SMN are detected with 
MANSMA12 and BD SMN antibodies from 1 d to 168 d at -20 oC (all tests twoway 
ANOVA; N > 3 mice). 
Fig. 3. Storage at lower temperatures improves preservation of SMN levels. 
(A) Representative blots demonstrating the effect of storage temperature (-20 oC 
vs -80 oC) on SMN levels at 1 d and 168 d (24 wk) (all blots prepared from intact 
tissue using MANSMA12 antibody). (B) Storage of samples at -80 oC preserved 
SMN levels above 50 % (grey horizontal line) for a longer time period than 
storage at -20 oC (*** P < 0.001; **** P < 0.0001; all tests two-way ANOVA; N > 3 
mice). 
Fig. 4. Storage of sample as tissue over protein extracts increases longevity 
of SMN preservation. (A) After 7 d storage at -20 oC less than 50 % (grey 
horizontal line) SMN levels remained detectable. (B) Storage of tissue rather 
than protein extracts consistently improved preservation of SMN levels (> 50 %) 
from 1 d to 168 d (24 wk) at -80 oC (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 
0.0001; all tests two-way ANOVA; N > 3 mice). 
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